Bioprocess Solutions About Us

Cell Therapy Manufacturing Technology Collaboration with HCATS

Hitachi Chemical Advanced Therapeutics Solutions and Saint-Gobain Announce Collaboration to Co-Develop and Commercialize Cell Therapy Manufacturing Technology

April 9, 2019 - Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and development of cell therapy products, and Saint-Gobain, a global leader in single-use solutions for the Biopharmaceutical industry, today announced a joint development agreement to co-develop and commercialize novel technology solutions, specifically for the cell therapy industry. This collaboration will allow both parties to leverage their decades of experience and unique capabilities to address manufacturing needs of cell therapy product developers and challenges such as CAR-T genetic modification and culture and closed in-process product sampling.   

“With hundreds of cell therapy clinical trials underway and being planned, the industry continues to be faced with challenges to properly prepare for sustainable commercialization of these promising therapies,” said Robert A. Preti, Ph.D., CEO and President of HCATS and General Manager of the Hitachi Chemical Regenerative Medicine Business Sector. “We are excited to partner with Saint-Gobain and look forward to supporting this growing industry by addressing our customers’ unique manufacturing challenges.”

“The collaboration between our two organizations provides an exciting opportunity to develop solutions to address the unique challenges associated with large scale production of patient specific therapies,” said Benjamin Le Quere, General Manager for the Saint-Gobain Bioprocess Solutions business unit.  “We are confident that together, HCATS and Saint-Gobain can create innovative, scalable production processes for this industry.”Image removed.